Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) Phase 2a Trial
Johns Hopkins University
120 participants
Oct 10, 2022
INTERVENTIONAL
Conditions
Summary
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).
Eligibility
Inclusion Criteria11
- Confirmed diagnosis of spontaneous, non-traumatic ICH.
- mL ≤ ICH ≤ 60 mL (confirmed via diagnostic and stability CT scans utilizing volumetric assessment)
- Participants receiving anticoagulants are eligible upon reversal and stability within 24hrs after onset of ICH symptoms
- Age ≥ 18 years
- Able to receive first dose of test article ≤ 24h after onset of ICH symptoms
- NIHSS score ≥ 2 at randomization or Glasgow Coma Scale ≥ 5 at randomization
- Controlled blood pressure (systolic BP < 180 mm Hg) at randomization.
- Premorbid magnetic resonance spectroscopy (mRS) of 0-2
- Has adequate venous access
- No planned surgical intervention except EVD
- Written informed consent from the patient or legally authorized representative (LAR)
Exclusion Criteria12
- Unstable hematoma defined as > 6 mL increase as compared to previous CT volume taken at least 6 hours apart within 24 hrs after onset of ICH symptoms.
- Anticipated neurosurgical evacuation by open surgery or minimally invasive surgery with or without Alteplase (EVD allowed).
- Uncontrolled temp >38.5˚C at enrollment.
- Signs of intracranial infection or emergence of a systemic infection
- Is pregnant or lactating
- Signs of liver and kidney chronic disease (i.e. creatinine >2, bilirubin > 3, receiving dialysis)
- Non-reversible bleeding diathesis
- Used any chronic immunosuppressants or chronic anti-inflammatory drugs (excluding low-dose aspirin), by any route of administration within the past 7 days.
- Anticipated withdrawal of life-sustaining therapies within the first week after admission.
- In the opinion of the investigator, patient has any contraindication to the planned study assessments.
- In the opinion of the investigator, patient has a condition that could interfere with the proposed treatment or unacceptably increase the individual's risk by participating in the study.
- Concomitant enrollment in another acute interventional study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05020535